Abstract:Pharmacological studies have indirectly shown that necroptosis participates in ischemic neuronal death. However, its mechanism has yet to be elucidated in the ischemic brain. TNFα-triggered RIPK1 kinase activation could initiate RIPK3/MLKL-mediated necroptosis under inhibition of caspase-8. In the present study, we performed middle cerebral artery occlusion (MCAO) to induce cerebral ischemia in rats and used immunoblotting and immunostaining combined with pharmacological analysis to study the mechanism of necroptosis in ischemic brains. In the ipsilateral hemisphere, we found that ischemia induced the increase of (i) RIPK1 phosphorylation at the Ser166 residue (p-RIPK1), representing active RIPK1 kinase and (ii) the number of cells that were double stained with P-RIPK1 (Ser166) (p-RIPK1+) and TUNEL, a label of DNA double-strand breaks, indicating cell death. Furthermore, ischemia induced activation of downstream signaling factors of RIPK1, RIPK3 and MLKL, as well as the formation of mature interleukin-1β (IL-1β). Treatment with necrostatin-1 (Nec-1), an inhibitor of necroptosis, significantly decreased ischemia-induced increase of p-RIPK1 expression and p-RIPK1+ neurons, which showed protection from brain damage. Meanwhile, Nec-1 reduced RIPK3, MLKL and p-MLKL expression levels and mature IL-1β formation in Nec-1 treated ischemic brains. Our results clearly demonstrated that phosphorylation of RIPK1 at the Ser166 residue was involved in the pathogenesis of necroptosis in the brains after ischemic injury. Nec-1 treatment protected brains against ischemic necroptosis by reducing the activation of RIPK1 and inhibiting its downstream signaling pathways. These results provide direct in vivo evidence that phosphorylated RIPK1 (Ser 166) plays an important role in the initiation of RIPK3/MLKL-dependent necroptosis in the pathogenesis of ischemic stroke in the rodent brain.

Necrostatin-1: a promising compound for neurological disorders

Inhibition of Receptor-Interacting Protein 3 Upregulation and Nuclear Translocation Involved in Necrostatin-1 Protection Against Hippocampal Neuronal Programmed Necrosis Induced by Ischemia/reperfusion Injury.

Necrostatin-1 Attenuates Inflammatory Response and Improves Cognitive Function in Chronic Ischemic Stroke Mice

The Neuroprotective Effects of Necrostatin-1 on Subarachnoid Hemorrhage in Rats are Possibly Mediated by Preventing Blood-Brain Barrier Disruption and RIP3-Mediated Necroptosis.

Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.

Necrostatin-1 Ameliorates Peripheral Nerve Injury-Induced Neuropathic Pain by Inhibiting the RIP1/RIP3 Pathway

Necroptosis inhibitors: mechanisms of action and therapeutic potential

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Necroptosis in Neuronal Injury and Neuroprotective Effects of Necrostatins

Necroptosis, a Novel Type of Programmed Cell Death, Contributes to Early Neural Cells Damage after Spinal Cord Injury in Adult Mice.

Molecular Insights into the Mechanism of Necroptosis: The Necrosome as a Potential Therapeutic Target

Necrostatin-1 Prevents Necroptosis in Brains after Ischemic Stroke Via Inhibition of RIPK1-Mediated RIPK3/MLKL Signaling

Discovery and optimization of 3-(indolin-5-yloxy)pyridin-2-amine derivatives as potent necroptosis inhibitors

The Potential Role of Necroptosis in Clinical Diseases (Review)

Mitochondrial Mechanisms of Necroptosis in Liver Diseases

Protein phosphorylation and kinases: Potential therapeutic targets in necroptosis

Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity

Identification of Piperlongumine as Potent Inhibitor of Necroptosis

Necrosulfonamide Inhibits Necroptosis by Selectively Targeting the Mixed Lineage Kinase Domain-Like Protein

Generation of small molecules to interfere with regulated necrosis

Structural Basis of RIP1 Inhibition by Necrostatins.